Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040417 · ClinicalTrials.gov registry record · Phase 2
Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies
A Phase 2 study, sponsored by Baylor College of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00040417 is a Phase 2 study that was terminated before completion, run by Baylor College of Medicine. The registered enrollment target is 15 participants.
The verdict
NCT00040417, a Phase 2 study, was terminated before completion, sponsored by Baylor College of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The major goal of this study is to determine the risks and benefits of stem cell transplants in combination with a newer, less toxic conditioning chemotherapy treatment in patients with severe sickle cell disease (SCD) or sickle hemoglobin variants (hemoglobin SC or hemoglobin SB0/+), or homozygous b0/+ thalassemia or severe B0/+ thalassemia variants. Participation in this project will be for one year, with follow up evaluations done every 6 months thereafter for 10 years or until participants are 18 years old.
Interventions
- DRUG FLUDARABINE
- PROCEDURE Total Body Irradiation
- DRUG FK506
- DRUG CAMPATH-IH
- DRUG G-SCF (Granulocyte-colony stimulating factor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2000-08 |
| Est. Completion | 2003-11-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00040417
The ClinicalTrials.gov registry entry for NCT00040417 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which FLUDARABINE is the first listed.
NCT00040417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00040417 about?
NCT00040417 is a clinical study titled "Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies". The major goal of this study is to determine the risks and benefits of stem cell transplants in combination with a newer, less toxic conditioning chemotherapy treatment in patients with severe sickle cell disease (SCD) or sickle hemoglobin variants (hemoglobin SC or hemoglobin SB0/+), or homozygous ...
What is the current status of trial NCT00040417?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2000-08. Estimated completion is 2003-11-21.
What interventions are being tested in trial NCT00040417?
The interventions under investigation include: FLUDARABINE (DRUG), Total Body Irradiation (PROCEDURE), FK506 (DRUG), CAMPATH-IH (DRUG), G-SCF (Granulocyte-colony stimulating factor) (DRUG).
Who is sponsoring clinical trial NCT00040417?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.